Zydus Cadila receives final approval from the USFDA for Nateglinide Tablets USP

Zydus Cadila has received the final approval from the USFDA to market Nateglinide Tablets USP in strengths of 60 mg and 120 mg. The drug is an oral anti-diabetic agent used in the management of Type 2 diabetes mellitus and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.